Literature DB >> 16107963

Hepatitis C virus genotype 1a NS5A pretreatment sequence variation and viral kinetics in African American and white patients.

Jennifer E Layden-Almer1, Carla Kuiken, Ruy M Ribeiro, Kevin J Kunstman, Alan S Perelson, Thomas J Layden, Steven M Wolinsky.   

Abstract

In hepatitis C virus (HCV) infection, race is a determinant of treatment response and interferon (IFN) effectiveness. Here, we investigated whether there were differences in the pretreatment viral strains between African American patients and white patients and whether these differences correlated with viral kinetics. IFN effectiveness was calculated using a viral kinetic model. The HCV NS5A region from 21 treated patients with HCV genotype 1a was sequenced and analyzed. White patients displayed more mutations in the V3 region (mean+/-SD, 4.5+/-1.4 vs. 2.9+/-1.6; P=.016), and treatment responders tended to have more mutations in this region than did nonresponders. There was a significant positive correlation between IFN effectiveness and the number of mutations in the V3 region (P=.03). There was no clustering of strains by race, treatment response, or IFN effectiveness in phylogenetic analyses. The results of this study, in conjunction with those of a previous study illustrating the impaired IFN effectiveness in African Americans, suggest a role for host-related factors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16107963     DOI: 10.1086/432760

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Hepatitis C hypervariable region 1: association of reduced selection pressure in african americans with treatment failure.

Authors:  Vicki M Park; Barbara C Mason; Julia Krushkal; Rongling Li; Caroline Riely; Jaquelyn Fleckenstein
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

2.  Evidence of distinct populations of hepatitis C virus in the liver and plasma of patients co-infected with HIV and HCV.

Authors:  Jason T Blackard; Gang Ma; Satarupa Sengupta; Christina M Martin; Eleanor A Powell; M Tarek Shata; Kenneth E Sherman
Journal:  J Med Virol       Date:  2014-04-30       Impact factor: 2.327

Review 3.  BK polyomavirus diversity-Why viral variation matters.

Authors:  Jason T Blackard; Stella M Davies; Benjamin L Laskin
Journal:  Rev Med Virol       Date:  2020-03-03       Impact factor: 6.989

4.  Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C.

Authors:  Kazuaki Chayama; C Nelson Hayes; Kentaro Yoshioka; Hisataka Moriwaki; Takashi Okanoue; Shotaro Sakisaka; Tetsuo Takehara; Makoto Oketani; Joji Toyota; Namiki Izumi; Yoichi Hiasa; Akihiro Matsumoto; Hideyuki Nomura; Masataka Seike; Yoshiyuki Ueno; Hiroshi Yotsuyanagi; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2011-01-19       Impact factor: 7.527

5.  Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians.

Authors:  Curtis L Cooper; Robert J Bailey; Vince G Bain; Frank Anderson; Eric M Yoshida; Mel Krajden; Paul Marotta
Journal:  Can J Gastroenterol       Date:  2008-08       Impact factor: 3.522

6.  Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy.

Authors:  Maureen J Donlin; Nathan A Cannon; Ermei Yao; Jia Li; Abdus Wahed; Milton W Taylor; Steven H Belle; Adrian M Di Bisceglie; Rajeev Aurora; John E Tavis
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

7.  Variability of the polymerase gene (NS5B) in hepatitis C virus-infected women.

Authors:  Jason T Blackard; Gang Ma; Berkeley N Limketkai; Jeffrey A Welge; Peter D Dryer; Christina M Martin; Yoichi Hiasa; Lynn E Taylor; Kenneth H Mayer; Denise J Jamieson; Kenneth E Sherman
Journal:  J Clin Microbiol       Date:  2010-09-01       Impact factor: 5.948

8.  Analysis of a non-structural gene reveals evidence of possible hepatitis C virus (HCV) compartmentalization.

Authors:  Jason T Blackard; Gang Ma; Jeffrey A Welge; Christina M Martin; Kenneth E Sherman; Lynn E Taylor; Kenneth H Mayer; Denise J Jamieson
Journal:  J Med Virol       Date:  2012-02       Impact factor: 2.327

9.  Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.

Authors:  Pascal Veillon; Christopher Payan; Hélène Le Guillou-Guillemette; Catherine Gaudy; Françoise Lunel
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

10.  Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.

Authors:  P Muñoz de Rueda; J Casado; R Patón; D Quintero; A Palacios; A Gila; R Quiles; J León; A Ruiz-Extremera; J Salmerón
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.